xMAP^® NeoPlex4^™

Luminex is nearing the completion of NeoPlex4, a multiplexed assay and fully automated, walk-away testing platform for newborn screening. The initial NeoPlex panel will test four analytes simultaneously, T4, TSH, 17OHP and total IRT. These high-volume screening assays test newborn infants for congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH), and (CF) cystic fibrosis (phenotypic). Each of these conditions can cause severe mental and physical disability if untreated. If detected early through testing, effective treatment can be initiated. Multiplexing these tests together from one blood spot punch offers significant improvements in testing efficiency, which is a significant benefit to newborn screening laboratories. Neoplex_Punch_Image

From a single bloodspot punch, your lab can achieve multiple benefits such as workflow improvements, increased throughput, test consolidation and sample preservation.One punch. Multiple results.

Simplify your laboratory workflow by getting four tests* from one bloodspot punch
Fewer instruments required, fewer microtiter plates used, less technician time needed and less maintenance
T4 and TSH results with the initial screen - reduce reflex testing and improve lab turn around time
Less sample required allows more sample for other tests you may want to add later
Built on the proven, flexible xMAP Technology platform

For more information call Luminex at 888.219.8020 or email: info@luminexcorp.com

*Assay in development - T4, TSH, 17-OHP, and total IRT. The performance characteristics of this assay have not been established. It is not currently available in any market.

xMAP® NeoPlex4™

xMAP^® NeoPlex4^™